Information Provided By: 
Fly News Breaks for January 12, 2017
TSRO
Jan 12, 2017 | 07:06 EDT
Credit Suisse analyst Alethia Young says that after speaking to TESARO management, she believes the company's Complete Response Letter seems "relatively minor." The analyst expects it to take couple months to coordinate FDA feedback and that the IV formulation could be approved late in the first half of 2017. She keeps her estimates unchanged for TESARO and maintains an Outperform rating on the stock with a $151 price target.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
